rheumatoid arthritis

Showing 15 posts of 66 posts found.

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

June 30, 2017
Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …


Celltrion biosimilar proves effectiveness in lymphoma and rheumatoid arthritis

June 14, 2017
Research and Development Cellltrion, Truxima, biosimilar, lymphoma, rheumatoid arthritis, rutiximab

Celltrion Healthcare has revealed new data which validates its biosimilar Truxima (CT-P10) as non-inferior to its reference product rituximab in …


Pfizer receive European approval for arthritis drug

March 27, 2017
Sales and Marketing Pfizer, rheumatoid arthritis

Following on from the positive opinion given to Xeljanz in January of this year, Pfizer’s drug has now been given …


Assay opens way to autoantibodies treatment for rheumatoid arthritis

February 27, 2017
Research and Development, Sales and Marketing rheumatoid arthritis

A new discovery, conducted by researchers at the NYU Langone Medical Center and the University of Pittsburgh, has pointed towards …


Amgen drug pair become first Humira biosimilars to win EU approval

January 30, 2017
Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis

Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …


GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

September 13, 2016
Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …

Pfizer launches legal action to block Xeljanz copies in India

September 9, 2016
Medical Communications, Sales and Marketing Pfizer, Sun Pharma, Xeljanz, Zydus Cadila, rheumatoid arthritis

Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts …


European Commission approves new RA treatment from BMS

September 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis

Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …

Experimental stem cell treatment shows promise in rheumatoid arthritis

August 10, 2016
Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment

Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …


AbbVie files lawsuit against Amgen over Humira copy

August 8, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …


Top ten stories in the pharmaceutical industry this week

August 5, 2016
Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …


CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment

July 25, 2016
Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis

Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …


US FDA committee recommends approval for Amgen’s biosimilar of AbbVie’s Humira

July 13, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, Humira, US FDA, biosimilar, drug approval, drug trial, inflammatory diseases, rheumatoid arthritis

One of the world’s bestselling drug may soon have competition in the US markets after the regulators backed a biosimilar …

Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis

July 13, 2016
Research and Development, Sales and Marketing Cimzia, NICE, UCB, regulation, rheumatoid arthritis

The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or …

Latest content